Related Experiment Video
Updated: Dec 11, 2025
01:37
A Preterm Rat Model for Pain Studies
Published on: February 9, 2024
646
PRDM12: New Opportunity in Pain Research
Sophie Imhof1, Tomislav Kokotović2, Vanja Nagy2
1Department of Neurology, Medical University of Vienna, Vienna, Austria.
Trends in Molecular Medicine
|August 24, 2020
Summary
Newly identified PRDM12 gene causes congenital insensitivity to pain, a disorder where individuals cannot feel pain. Understanding its function offers new therapeutic avenues for various pain conditions.
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- Congenital insensitivity to pain (CIP) is a rare disorder characterized by the inability to perceive pain.
- The PRDM12 gene has been recently identified as a causative factor in a subset of CIP cases.
Purpose of the Study:
- To elucidate the (patho)physiology of PRDM12 gene function in relation to pain perception.
- To explore the therapeutic potential and challenges associated with targeting PRDM12 for pain disorders.
Main Methods:
- Literature review and analysis of existing genetic and functional data related to PRDM12.
- Discussion of the molecular mechanisms underlying PRDM12's role in nociception.
Main Results:
- PRDM12 plays a critical role in the development and function of pain-sensing pathways.
- Dysfunction of PRDM12 leads to impaired pain signaling, resulting in congenital insensitivity to pain.
Conclusions:
- The identification of PRDM12 as a causative gene for CIP provides crucial insights into pain pathways.
- Targeting PRDM12 presents a promising, yet challenging, avenue for developing novel treatments for diverse pain conditions.
